<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41873">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01911624</url>
  </required_header>
  <id_info>
    <org_study_id>S54881</org_study_id>
    <nct_id>NCT01911624</nct_id>
  </id_info>
  <brief_title>Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia</brief_title>
  <official_title>Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia. A Prospective Randomized Controlled Academic Single-centre Feasibility Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and efficacy of direct thrombin inhibitors versus enoxaparin in patients with
      staphylococcus aureus bacteraemia.

      The study hypothesizes that inhibition of the coagulase-activity of S. aureus by direct
      thrombin inhibitors is safe and translates into a better outcome of patients with S. aureus
      bacteremia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Primary Safety Outcome is the occurence of clinically-relevant bleeding events</measure>
    <time_frame>From date of randomization up to end of study drug + 3 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The primary efficacy outcome is the occurence of metastatic infection</measure>
    <time_frame>From randomization until month 3</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>as documented with a PET-CTscan in eligible patients on D7-10 or clinically-overt metastatic infectious foci</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Laboratory markers of coagulation</measure>
    <time_frame>From randomization until D7-10</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory markers of inflammation</measure>
    <time_frame>From randomization until D7-10</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Clinical outcomes after S. aureus bacteremia</measure>
    <time_frame>From randomization until M3</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Staphylococcus Aureus Bacteraemia</condition>
  <arm_group>
    <arm_group_label>direct thrombin inhibition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dabigatran 110 mg BID, po argatroban (0.5 - 1 Âµg/kg/min) if peroral therapy is not possible</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>enoxaparin 40 mg od, sc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>direct thrombin inhibition</intervention_name>
    <arm_group_label>direct thrombin inhibition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin</intervention_name>
    <arm_group_label>enoxaparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive blood culture for stahylococcus aureus

          -  Symptoms or signs of infection

          -  Indication for thromboprophylaxis

        Exclusion Criteria:

          -  Contraindication for thromboprophylaxis

          -  Significant active bleeding or risk of excessive bleeding

          -  Heparine-induced thrombocytopenia

          -  Severe liver and kidney disease

          -  Pregnancy and lactation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Verhamme, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bloedings-en vaatziekten, UZ Gasthuisberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Verhamme, PI</last_name>
    <phone>003216343491</phone>
    <email>Peter.verhamme@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Debaveye, study coordinator</last_name>
    <phone>003216343491</phone>
    <email>Barbara.debaveye@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>KUleuven/UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Verhamme, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 25, 2013</lastchanged_date>
  <firstreceived_date>June 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Peter Verhamme</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombin</mesh_term>
    <mesh_term>Antithrombin Proteins</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Antithrombins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
